The availability of highly effective CFTR modulators is revolutionizing the treatment of cystic
fibrosis (CF) and drastically improving outcomes. MRI-based imaging modalities are now …

Objectives To investigate whether 3D phase-resolved functional lung (PREFUL)-MRI
parameters are suitable to measure response to elexacaftor/tezacaftor/ivacaftor (ETI) …

Background The triple combination of the cystic fibrosis transmembrane regulator (CFTR)
modulators elexacaftor, tezacaftor, and ivacaftor (hereafter, elexacaftor/tezacaftor/ivacaftor) …

Background Lung magnetic resonance imaging (MRI) with ultrashort echo‐times (UTE‐MRI)
allows high‐resolution and radiation‐free imaging of the lung structure in cystic fibrosis (CF) …

Purpose To assess the feasibility of monitoring the effects of elexacaftor-tezacaftor-ivacaftor
(ETI) therapy on lung ventilation and perfusion in people with cystic fibrosis (CF), using …

This is a prospective, observational study involving three Cystic Fibrosis (CF) adult patients,
evaluating the changes in chest magnetic resonance imaging (MRI) three months after the …

Abstract Background Therapy with Elexacaftor/Tezacaftor/Ivacaftor (ETI) was recently
approved for adult cystic fibrosis (CF) patients with at least one F508del mutation. However …

Background The CFTR modulator elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) leads to
significant improvement in the symptoms and spirometry of people with cystic fibrosis …

Abstract Rationale and Objectives Cystic fibrosis transmembrane conductance regulator
(CFTR) modulators have revolutionised the treatment of cystic fibrosis (CF). Chest computed …

Rationale: We recently demonstrated that triple-combination CFTR (cystic fibrosis
transmembrane conductance regulator) modulator therapy with elexacaftor/tezacaftor …